Cosmo Pharmaceuticals N.V. (CMOPF)
USD 55.0
(0.0%)
USD 55.0
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 942 Thousand EUR | -88.35% |
| 2022 | 8.08 Million USD | -95.91% |
| 2021 | 197.79 Million USD | -4.93% |
| 2020 | 208.04 Million USD | 16.48% |
| 2019 | 178.59 Million USD | 0.53% |
| 2018 | 177.65 Million EUR | 12116.77% |
| 2017 | 1.45 Million EUR | -4.32% |
| 2016 | 1.51 Million EUR | -0.84% |
| 2015 | 1.53 Million EUR | -82.84% |
| 2014 | 8.93 Million EUR | -8.52% |
| 2013 | 9.76 Million EUR | -11.58% |
| 2012 | 11.04 Million EUR | 759.81% |
| 2011 | 1.28 Million EUR | -40.99% |
| 2010 | 2.17 Million EUR | 32.52% |
| 2009 | 1.64 Million EUR | -43.44% |
| 2008 | 2.9 Million EUR | -20.64% |
| 2007 | 3.65 Million EUR | -23.52% |
| 2006 | 4.78 Million EUR | -65.58% |
| 2005 | 13.89 Million EUR | -8.9% |
| 2004 | 15.25 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 714 Thousand EUR | 0.0% |
| 2024 Q2 | 714 Thousand EUR | 0.0% |
| 2023 Q2 | 8.25 Million USD | 492.75% |
| 2023 FY | 942 Thousand EUR | -88.35% |
| 2023 Q1 | 1.39 Million EUR | -82.78% |
| 2023 Q3 | 942 Thousand EUR | -88.58% |
| 2023 Q4 | 942 Thousand EUR | 0.0% |
| 2022 Q4 | 8.08 Million USD | 356.42% |
| 2022 FY | 8.08 Million USD | -95.91% |
| 2022 Q1 | 189.08 Million EUR | 11.86% |
| 2022 Q2 | 177.24 Million EUR | -6.26% |
| 2022 Q3 | 1.77 Million EUR | -99.0% |
| 2021 Q1 | 195.67 Million EUR | 18.44% |
| 2021 FY | 197.79 Million USD | -4.93% |
| 2021 Q2 | 166.91 Million EUR | -14.7% |
| 2021 Q3 | 195.77 Million EUR | 17.29% |
| 2021 Q4 | 169.02 Million EUR | -13.66% |
| 2020 Q4 | 165.2 Million EUR | -14.72% |
| 2020 FY | 208.04 Million USD | 16.48% |
| 2020 Q2 | 163.78 Million EUR | -9.26% |
| 2020 Q3 | 193.72 Million EUR | 18.28% |
| 2020 Q1 | 180.5 Million EUR | 10.51% |
| 2019 Q3 | 178.04 Million EUR | 9.82% |
| 2019 FY | 178.59 Million USD | 0.53% |
| 2019 Q1 | 181.85 Million EUR | 15.37% |
| 2019 Q2 | 162.12 Million EUR | -10.85% |
| 2019 Q4 | 163.33 Million EUR | -8.26% |
| 2018 FY | 177.65 Million EUR | 12116.77% |
| 2018 Q3 | 182.98 Million EUR | 4940.9% |
| 2018 Q2 | 3.63 Million EUR | -18.82% |
| 2018 Q1 | 4.47 Million EUR | 16.84% |
| 2018 Q4 | 157.62 Million EUR | -13.86% |
| 2017 Q4 | 3.82 Million EUR | -15.39% |
| 2017 Q2 | 4.25 Million EUR | -6.27% |
| 2017 Q1 | 4.53 Million EUR | 1.69% |
| 2017 FY | 1.45 Million EUR | -4.32% |
| 2017 Q3 | 4.52 Million EUR | 6.4% |
| 2016 Q4 | 4.46 Million EUR | -10.97% |
| 2016 Q2 | 5.83 Million EUR | -12.19% |
| 2016 Q1 | 6.64 Million EUR | 0.96% |
| 2016 FY | 1.51 Million EUR | -0.84% |
| 2016 Q3 | 5 Million EUR | -14.08% |
| 2015 Q2 | 7.98 Million EUR | -6.91% |
| 2015 FY | 1.53 Million EUR | -82.84% |
| 2015 Q4 | 6.57 Million EUR | -10.39% |
| 2015 Q3 | 7.34 Million EUR | -8.11% |
| 2015 Q1 | 8.58 Million EUR | -3.89% |
| 2014 FY | 8.93 Million EUR | -8.52% |
| 2014 Q4 | 8.93 Million EUR | -20.76% |
| 2014 Q3 | 11.27 Million EUR | 28.14% |
| 2014 Q2 | 8.79 Million EUR | -27.42% |
| 2014 Q1 | 12.11 Million EUR | 24.14% |
| 2013 Q3 | 13.21 Million EUR | 20.95% |
| 2013 FY | 9.76 Million EUR | -11.58% |
| 2013 Q4 | 9.76 Million EUR | -26.11% |
| 2013 Q2 | 10.92 Million EUR | -21.95% |
| 2013 Q1 | 13.99 Million EUR | 26.78% |
| 2012 Q4 | 11.04 Million EUR | 0.0% |
| 2012 Q2 | 876 Thousand EUR | 0.0% |
| 2012 FY | 11.04 Million EUR | 759.81% |
| 2011 Q2 | 1.77 Million EUR | 0.0% |
| 2011 FY | 1.28 Million EUR | -40.99% |
| 2011 Q4 | 1.28 Million EUR | 0.0% |
| 2010 Q2 | 2.56 Million EUR | 0.0% |
| 2010 Q4 | 2.17 Million EUR | 0.0% |
| 2010 FY | 2.17 Million EUR | 32.52% |
| 2009 FY | 1.64 Million EUR | -43.44% |
| 2009 Q4 | 1.64 Million EUR | 0.0% |
| 2008 FY | 2.9 Million EUR | -20.64% |
| 2007 FY | 3.65 Million EUR | -23.52% |
| 2006 FY | 4.78 Million EUR | -65.58% |
| 2005 FY | 13.89 Million EUR | -8.9% |
| 2004 FY | 15.25 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AstraZeneca PLC | 22.33 Billion USD | 99.996% |
| Bristol-Myers Squibb Company PFD CONV 2 | 38.18 Billion USD | 99.998% |
| CSPC Pharmaceutical Group Limited | 107.05 Million USD | 99.12% |
| Clarus Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Novartis AG | 20.03 Billion USD | 99.995% |
| PT Kalbe Farma Tbk. | 19.39 Million USD | 95.142% |